Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
DDXSQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	49.2K 44.14K 40.81K 36.96K 69.05K 4.69M 69.89K 488K 194K 2.45M 185K 181K 7.78M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.75M 4.39M 3.97M 7.42M 504M 7.51M 52.47M 20.9M 264M 19.85M 19.43M 837M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
11/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ELI LILLY AND COMPANY	+0.50%	+0.36%	+55.89%	+129.96%	1,143B
JOHNSON & JOHNSON	+0.86%	+4.50%	+42.43%	+86.15%	647B
ABBVIE INC.	-0.14%	-1.07%	+25.42%	+105.85%	506B
ROCHE HOLDING AG	-0.05%	+2.28%	+49.14%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-4.97%	+60.15%	+37.06%	350B
NOVARTIS AG	+0.34%	+2.15%	+25.26%	+54.27%	293B
ASTRAZENECA PLC	-0.45%	+1.16%	+1.74%	+26.08%	265B
AMGEN INC.	+0.87%	+2.94%	+55.18%	+72.74%	242B
GILEAD SCIENCES, INC.	+0.08%	+1.72%	+32.15%	+107.78%	197B
Average	+0.42%	+0.76%	+38.60%	+76.40%	402.75B
Weighted average by Cap.	+0.77%	+0.71%	+42.63%	+89.02%

	2014	2015
Net sales	26.11M 23.43M 21.66M 19.62M 36.65M 2.49B 37.09M 259M 103M 1.3B 97.99M 95.92M 4.13B	17.88M 16.05M 14.83M 13.44M 25.1M 1.7B 25.4M 177M 70.65M 891M 67.11M 65.7M 2.83B
Net income	-8.47M -7.6M -7.02M -6.36M -11.88M -806M -12.03M -83.97M -33.45M -422M -31.77M -31.1M -1.34B	-7.17M -6.43M -5.94M -5.38M -10.06M -682M -10.18M -71.07M -28.31M -357M -26.89M -26.32M -1.13B
Net Debt	-198K -178K -164K -149K -278K -18.86M -281K -1.96M -782K -9.87M -743K -727K -31.33M	5.24M 4.7M 4.35M 3.94M 7.36M 499M 7.44M 51.98M 20.7M 261M 19.67M 19.25M 829M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile